Vaxcyte, Inc. annual report, FY2020

Business context and reporting period

Vaxcyte, Inc. filed this Form 10-K for the fiscal year ended December 31, 2020. It is a preclinical vaccine developer with no approved products and no product revenue. Its lead candidate, VAX-24, is an investigational 24-valent pneumococcal conjugate vaccine; the pipeline also includes VAX-XP, VAX-A1 for Group A Strep, and VAX-PG for periodontitis.

Financial performance and liquidity

Revenue and operating margins are not meaningful because the company has no product sales. Cash and cash equivalents were $386.2 million at year-end, versus $59.0 million a year earlier; total current assets were $389.0 million and current liabilities $46.9 million. Total liabilities were $47.0 million. No capital lease liability remained at year-end, and the filing reports no off-balance-sheet arrangements.

Financing cash inflow was $374.9 million, chiefly $264.0 million net proceeds from the June 2020 IPO and $109.9 million from Series D preferred stock. The preferred shares converted to common stock upon the IPO. Operating cash use was lower than the net loss partly because accounts payable and accrued manufacturing balances increased, including deferred Lonza completion payments. The company said existing cash was expected to fund operations through anticipated VAX-24 Phase 1/2 adult topline data in late 2022 or early 2023, but additional capital would be needed before pivotal trials.

Material changes versus the prior period

Net loss increased 77.5% year over year. R&D expense rose 61.3%, mainly from VAX-24 manufacturing and outsourced research activity; G&A expense rose 87.4%, reflecting staffing, professional services, and public-company costs. For the unaudited fourth quarter, net loss was $20.7 million, compared with $14.6 million in Q4 2019; quarterly operating expenses were $19.5 million versus $15.8 million.

The 2020 loss included $2.5 million of CARB-X grant income and $2.4 million of foreign-currency transaction losses. FY 2019 included a $3.2 million gain from a change in fair value of a preferred-stock tranche liability, with no comparable gain in 2020.

Outlook, risks, and unusual items

• Management expected to submit the VAX-24 IND between January and June 2022, begin a Phase 1/2 adult study thereafter, and report topline data in late 2022 to early 2023. The proposed regulatory path using immune-response endpoints remains subject to FDA feedback; field efficacy studies or additional trials may be required.
• VAX-24 manufacturing process issues and Lonza scheduling and capacity constraints delayed the drug-substance campaign and changed the IND timeline. Manufacturing had resumed, but further delays were possible.
• The company relies on third parties, particularly Lonza for manufacturing and Sutro Biopharma for critical extract and reagents. Disruptions, quality issues, or inability to scale could delay development.
• COVID-19 had slowed raw-material supply chains, delayed equipment qualification, and limited in-person manufacturer oversight. Further effects on operations, clinical timelines, and access to capital remained uncertain.
• Vaxcyte had no products approved and expected substantial future losses and funding needs. Competition includes larger vaccine companies with advanced pneumococcal candidates; commercial success also depends on regulatory approval, ACIP recommendations, coverage, reimbursement, and market acceptance.
• The CARB-X award supported VAX-A1 development; the initial funding limit was reached in December 2020, and the company was submitting a proposal for the next funding period. Potential total award funding was contingent on options and milestones.
• The financial statements received an unqualified audit opinion. The auditor was not engaged to audit internal control effectiveness; management reported disclosure controls effective at a reasonable assurance level.

Important facts for investors to verify

• Whether VAX-24 manufacturing progress supports the revised IND and clinical-study schedule, and whether Lonza capacity or process changes create additional delays.
• How long the $386.2 million year-end cash balance will fund operations as development spending increases, and the timing and terms of future financing.
• Whether FDA accepts the proposed immunogenicity endpoints and non-inferiority approach, or requires field efficacy or other additional studies.
• Whether preclinical results for VAX-24 and other candidates translate into human safety and immune-response outcomes.
• Progress on alternate supply arrangements, including the second supplier for Sutro materials and the company’s dependence on external manufacturers.
• Whether CARB-X approves further VAX-A1 funding and whether grant support remains available for planned development.